Browse studies

Find your next paid study

17 recruiting studies matching your filters

Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients With Limited Metastatic Disease That Failed First-Line Systemic Therapy

This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor his…

Personalized MedicineOligometastatic DiseaseFeasibility

Estimated

~$10 – $6,250

Good Samaritan Hospital Medical Center, New YorkNCT06842030

Phase 2

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination wi…

Oligometastatic Prostate Cancer

Estimated

~$10 – $7,500

Catherine SpinaNCT05915442

Phase 3

Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)

This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereot…

Oligometastatic Malignant Solid Neoplasm

Estimated

~$10 – $6,250

University of California, San DiegoNCT06587490

Phase 1

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab …

Prostate Cancer PatientsNon-castrate Prostate CancerRecurrent Prostate Cancer+1 more

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT07090148

Observational

MC230504 Safe Omission of Pelvic Lymph Node Dissection (SOuND ) During Radical Prostatectomy: Diagnostic Accuracy of rhPSMA-7.3(18F) PET/CT, mpMRI and Patient Clinical Factors to Predict Lymph Node Metastasis

This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) for identifyi…

Localized Prostate CarcinomaOligometastatic Prostate CarcinomaStage I Prostate Cancer AJCC v8+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06389786